Investor skepticism underscores challenges in demonstrating robust clinical value in psychedelic therapeutics for depression. < Back Compass Pathways' Phase 3 Psilocybin Readout Raises Efficacy Questions Despite Meeting Primary Endpoint Investor skepticism underscores challenges in demonstrating robust clinical value in psychedelic therapeutics for depression. In a long-anticipated clinical milestone for the psychedelics space, Compass Pathways reported topline results from a pivotal Phase 3 study of its proprietary psilocybin formulation, COMP360, in treatment-resistant depression (TRD). While the study met its primary endpoint, the magnitude of benefit and lack of detailed secondary outcomes left markets underwhelmed, sending shares tumbling by nearly 50% in early trading . The U.K.-based biotech enrolled 258 TRD patients, administering a single dose of COMP360 or placebo in a double-blind design, followed by psychological support. At six weeks, the psilocybin arm demonstrated a statistically significant 3.6-point reduction on the MADRS scale relative to placebo, a result Compass positioned as both clinically meaningful and a validation of its development approach. However, in an environment of growing competition and increasing investor scrutiny, the response was tepid. Analysts and key opinion leaders flagged the relatively modest separation from placebo, particularly in contrast to earlier Phase 2 data showing approximately a 6-point difference, and noted the absence of crucial secondary metrics such as remission and response rates. RBC Capital Markets analyst Leonid Timashev noted that in the absence of durability data or functional endpoints, a 3.6-point delta on MADRS may not be enough to drive investor confidence or payer differentiation. Futhermore, clinicians in their outreach indicated that a 4-point margin would be a minimum threshold of interest, with 5 points or more seen as indicative of a compelling treatment effect. This tempered enthusiasm may also reflect expectations shaped by recent competitors. GH Research, for example, reported promising results in an 81-patient trial of inhaled mebufotenin, a psilocybin analogue, showing nearly a 16-point placebo-adjusted reduction on the same scale at day eight. While direct comparisons are fraught due to protocol and timing differences, the contrast points towards a key challenge for Compass: demonstrating that COMP360 offers both efficacy and convenience superior to current alternatives. GH’s trial employed a titrated dose and evaluated outcomes at an earlier timepoint, which may have limited placebo response and enhanced effect size. These nuances matter, particularly in psychiatric trials where expectation effects are notoriously difficult to control. From a safety perspective, Compass reported no new signals, with its independent data monitoring committee confirming a consistent safety profile and no clinically meaningful imbalance in suicidality between treatment arms, a critical consideration in TRD populations. Still, commercial viability remains an open question. Johnson & Johnson’s Spravato ( esketamine ), an intranasal therapy for TRD approved in 2019, generated over $1 billion in sales last year, largely driven by a broader label and entrenched payer relationships. Compass, by contrast, is navigating an uncharted reimbursement landscape for psychedelic-assisted therapy, with questions remaining around scalability, infrastructure requirements, and healthcare provider training. Evercore ISI analyst Gavin Clark-Gartner downgraded the stock following the announcement, characterizing the outcome as insufficiently convincing. " With clinical and commercial question marks, the second [Phase 3 study] will remain a ‘show me’ story for investors in an increasingly competitive landscape,” he wrote. Those results, evaluating longer-term outcomes over a 26-week horizon, are expected in the second half of next year. Until then, Compass must contend not only with a skeptical market but with a rapidly evolving field that continues to challenge traditional notions of drug development in mental health. Author BioFocus Newsroom Previous Next

UK start-up's new platform promises to cut GLP-1 discontinuation rates by tailoring dose escalation to each patient's response. < Back Closed Loop Medicine Brings Personalised GLP-1 Dosing to the U.S with WeDosify UK start-up's new platform promises to cut GLP-1 discontinuation rates by tailoring dose escalation to each patient's response. Closed Loop Medicine Ltd (CLM), a UK-based leader in personalised pharmaceutical dosing, has announced the U.S. launch of WeDosify, its first commercially available product. The platform is designed to help clinicians improve long-term adherence to GLP-1 therapies by tailoring dose escalation and maintenance to each patient’s tolerability and treatment goals. Global demand for anti-obesity medicines continues to accelerate, with the market expected to grow from US$30 billion in 2024 to US$100 billion by 2030. Yet, despite their efficacy, up to 44% of patients stop GLP-1 therapy within six months, a figure that rises to 60% within a year, largely because of dose-related gastrointestinal side effects such as nausea and diarrhoea, as well as a lack of structured support for long-term use. WeDosify aims to address this problem by presenting data-driven, individualised dosing options for clinical review, updating recommendations in real time as a patient responds to treatment. The technology is informed by 29 studies and more than 15,000 patient profiles, underpinned by pharmacokinetic/pharmacodynamic modelling. A recent survey found that 91% of GLP-1 patients would be more likely to stay on treatment if supported by WeDosify. One respondent explained: “Having data helps you make personalized decisions and makes you more engaged with your weight loss journey.” Clinicians are already adopting the tool. Dr. Neese, from Amarillo Premier Research in Texas, commented: “I am delighted to have the opportunity to share WeDosify with my patients. It will enable me to work with each patient to determine a course of action that is genuinely personal to them, helping them to achieve lasting weight loss.” Kate Woolland, CEO of CLM, positioned the launch as a milestone: “WeDosify is the first product that offers genuinely personalized recommendations which update in real time to reflect how the patient is responding to the drug. For the first time, patients can see what their weight loss journey might look like and work alongside their clinician to make decisions about their health. This is a genuine gamechanger.” The timing is significant. Regulatory efforts such as the Right Drug Dose Now Act and the White House’s HTI-4 digital health commitment highlight growing emphasis on precision prescribing and reducing adverse drug events. Meanwhile, drug developers are increasingly focused on balancing GLP-1 efficacy with tolerability; slow, individualised titration schedules have been shown to improve patient outcomes in recent clinical studies. By tackling adherence, CLM hopes WeDosify will extend the undoubted benefits of GLP-1 therapy to more patients for longer, potentially setting a new standard for how weight-loss medicines are used in practice. Author BioFocus Newsroom Previous Next

< Back 4th March, 2025 San Francisco, CA 2025 Cell & Gene Therapy Summit Connect with Fellow Leaders Shaping Cell and Gene Therapy Development Following a value-packed European edition in London, the Charles River hosted Cell & Gene Therapy Summit returns to San Francisco this March. The sixth in a series of premier one-day events held in the world’s biggest biotech hubs, bringing together the leading experts, executives, and thought leaders in the CGT space to discuss and navigate critical challenges. Previous Register now Next

< Back 27th – 31st July, 2025 Chicago, IL ADLM 2025 Clinical Lab Expo ADLM 2025 Clinical Lab Expo (formerly known as the AACC Clinical Lab Expo) is the premier global laboratory medicine exposition. As the place to learn about the breakthrough innovations shaping the future of clinical testing and patient care, ADLM’s Clinical Lab Expo gives attendees the opportunity to browse 850+ exhibitors in person for the solutions to your lab-related needs. Previous Register now Next

< Back 13th – 14th November, 2025 Philadelphia, PA 5th Investigator-Initiated Trials Summit As investigator-initiated trials grow more intricate, your team needs the most up-to-date strategies on building successful IITs, forecasting budgets, achieving study milestones, and brainstorming innovative KPI strategies. Save the date for November 13-14 for DGE’s 5th Investigator Initiated Trials conference! Back by popular demand, our all-new agenda provides answers to your most urgent questions about the best practices for reviewing, selecting, and funding research investigators! Previous Register now Next

< Back Training the Immune System to Outlast Cancer Personalized RNA vaccines show long-term promise in pancreatic cancer, new study reports. Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), is one of the deadliest forms of cancer, with limited treatment options and a high rate of recurrence after surgery. However, a new study published in Nature reports that personalized RNA vaccines can train the immune system to fight back, potentially delaying or even preventing the return of the disease. One of the biggest hurdles in cancer treatment is getting the immune system to recognize and attack cancer cells. Cancer vaccines aim to do just that by targeting specific proteins, or "neoantigens," that are unique to the tumor. But in pancreatic cancer, which has relatively few mutations, this has been particularly challenging. The new study, led by researchers at Memorial Sloan Kettering Cancer Center, tackles this problem head-on with a novel approach: personalized RNA vaccines designed to prime the immune system to recognize and destroy cancer cells. A Personalized Approach The researchers conducted a phase I clinical trial involving 19 patients who had undergone surgery to remove their pancreatic tumors. After surgery, patients received a combination of treatments: a single dose of atezolizumab (an immune checkpoint inhibitor), followed by a personalized RNA vaccine called autogene cevumeran , and then a standard chemotherapy regimen known as mFOLFIRINOX. The vaccine was tailor-made for each patient, targeting up to 20 unique neoantigens—mutated proteins found only in their tumors. The goal was to train the immune system, specifically CD8+ T cells, to recognize and attack any remaining cancer cells, reducing the risk of recurrence. The results were striking. At a median follow-up of 3.2 years, patients who responded to the vaccine—meaning their immune systems produced a strong T cell response—had significantly longer recurrence-free survival compared to non-responders. In fact, the median recurrence-free survival for responders had not yet been reached, while non-responders had a median survival of just 13.4 months. Even more impressive was the longevity of the immune response. The vaccine-induced T cells were estimated to persist for an average of 7.7 years, with some clones potentially lasting for decades. These T cells not only stuck around but also remained functional, retaining their ability to recognise and attack cancer cells. This is a critical finding, as long-lasting immunity is essential for preventing cancer from coming back. How does it work? The vaccine works by introducing RNA sequences that encode the neoantigens into the body. These RNA sequences are packaged in lipid nanoparticles, which help deliver them to immune cells. Once inside, the immune cells use the RNA to produce the neoantigens, effectively training the immune system to recognize and attack cancer cells that display these same proteins. The study also revealed that the vaccine-induced T cells were mostly "de novo," meaning they were newly generated in response to the vaccine rather than pre-existing in the body. This is important because it suggests that the vaccine can kickstart an immune response even in patients whose immune systems haven’t naturally recognized the cancer. Using advanced single-cell RNA and TCR sequencing, the researchers tracked the behavior of these T cells over time. They found that the T cells went through several phases: first proliferating rapidly, then contracting, and finally settling into a long-lasting memory state. Importantly, these memory T cells retained their ability to kill cancer cells, even years after vaccination. In patients who experienced a recurrence, the tumors showed signs of "clonal pruning," meaning that the cancer cells targeted by the vaccine were largely eliminated. This suggests that the vaccine-induced T cells were actively working to keep the cancer in check. What does this mean for patients? For patients with pancreatic cancer, these findings are a beacon of hope. The study shows that it’s possible to generate a strong, long-lasting immune response against a cancer that has historically been very difficult to treat. While the results are still early and need to be confirmed in larger trials, the potential is enormous. The personalized nature of the vaccine is particularly exciting. By targeting the unique mutations in each patient’s tumor, the vaccine can potentially be adapted to treat a wide range of cancers, not just pancreatic cancer. This approach could be especially beneficial for cancers with low mutation rates, where traditional immunotherapy has struggled to make an impact. The researchers are already planning the next steps. A global randomized trial, called IMCODE 003, is underway to further test the efficacy of the vaccine in a larger group of patients. If successful, this could pave the way for a new era of personalized cancer vaccines, offering hope to patients with some of the most challenging forms of the disease. This study represents a significant leap forward in the fight against pancreatic cancer. By harnessing the power of personalized RNA vaccines, researchers have shown that it’s possible to train the immune system to recognize and attack cancer cells, potentially preventing recurrence and improving survival. While there’s still much work to be done, the results are a promising step toward a future where cancer vaccines could become a standard part of treatment, offering new hope to patients worldwide. Author BioFocus Newsroom Previous Next

< Back LIVX 2026 8th – 10th December, 2026 Dubai, UAE Hosting the most powerful global ecosystem for longevity, biotech, and investment. ! Widget Didn’t Load Check your internet and refresh this page. If that doesn’t work, contact us. Previous Next

Promising early data at CROI 2025 shows that HIV functional cure candidate, IMC-M113V, is well-tolerated and may offer prolonged viral suppression without the need for lifelong antiretroviral therapy. < Back Immunocore Unveils Promising HIV Functional Cure Data at CROI 2025 Promising early data at CROI 2025 shows that HIV functional cure candidate, IMC-M113V, is well-tolerated and may offer prolonged viral suppression without the need for lifelong antiretroviral therapy. Immunocore is a leading biotechnology company focused on developing cutting-edge therapies that harness the power of the immune system to treat a variety of cancers and infectious diseases. The company’s proprietary ImmTAC platform enables the development of novel immunotherapies that can target and destroy diseased cells with precision. Immunocore’s portfolio includes therapies for both oncology and infectious diseases, with a strong commitment to transforming the treatment landscape for patients worldwide. Immunocore Holdings plc (IMCR), a leader in immuno-oncology, has revealed groundbreaking early-stage data from its Phase 1/2 STRIVE trial of IMC-M113V, a novel candidate aimed at providing a functional cure for HIV. The data were presented in an oral session at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI). The multiple ascending dose (MAD) phase of the trial showed promising results, indicating that IMC-M113V is well-tolerated and capable of inducing dose-dependent viral control in HIV patients. These findings come as a major step forward in the ongoing quest to develop a treatment that could eliminate the need for lifelong antiretroviral therapy (ART). Notably, some patients demonstrated viral suppression lasting for up to 12 weeks after ART interruption, providing early evidence of the potential for long-term control. IMC-M113V, Immunocore’s most advanced HIV candidate, targets the virus in a unique manner, leveraging the company’s proprietary ImmTAC technology to activate the immune system’s T cells to target and destroy HIV-infected cells. The STRIVE trial is designed to evaluate the safety, tolerability, and efficacy of IMC-M113V at escalating doses, and these initial findings mark an important milestone in the development of a functional cure for HIV. “We are excited to share the early results from the STRIVE trial, which represent an important step toward potentially transforming the treatment landscape for people living with HIV,” said Dr. Anna Taylor, Chief Medical Officer at Immunocore. “While these data are still in the early stages, the ability of IMC-M113V to provide prolonged viral suppression without the need for ART is encouraging, and we look forward to continuing to explore its potential in future trial stages.” Immunocore emphasized that while the data is still in its early phase, the results suggest the potential of IMC-M113V to be a game-changer in the fight against HIV, offering hope for a functional cure that could reduce or eliminate the dependency on daily ART regimens. The company is continuing to test higher doses of IMC-M113V in the ongoing trial, with further data expected in the coming months. Researchers and clinicians alike are watching closely to see how these findings progress, as the development of a functional cure for HIV remains one of the most sought-after goals in the field of infectious disease. Author BioFocus Newsroom Previous Next

The recent collaboration between Lonza’s Synaffix and BigHat Biosciences exemplifies the growing convergence of biotechnology with machine learning to produce next-generation cancer therapies. < Back Advancing the Future of ADCs through Machine Learning: Lonza’s Synaffix and BigHat Biosciences Collaboration The recent collaboration between Lonza’s Synaffix and BigHat Biosciences exemplifies the growing convergence of biotechnology with machine learning to produce next-generation cancer therapies. Antibody-drug conjugates (ADCs) are at the forefront of oncology treatment, offering a targeted therapeutic approach that delivers potent drugs directly to cancer cells, thereby minimizing systemic toxicity. This partnership combines BigHat’s ML (machine learning)-based antibody design platform, Milliner™ , with Synaffix’s proprietary ADC technology to develop a highly differentiated, effective, and safe ADC pipeline. Synaffix and BigHat Biosciences: Pioneers in ADC Innovation ADCs are designed to selectively deliver cytotoxic agents to cancer cells by harnessing the specificity of antibodies. However, achieving both selectivity and efficacy remains a challenge due to the inherent complexity of the antibody-drug conjugate structure. This is where Synaffix’s ADC technology platform becomes instrumental. Comprised of GlycoConnect™ , HydraSpace® , and toxSYN® technologies, the Synaffix platform provides a comprehensive toolkit that optimizes ADC drug-like properties and enhances efficacy and tolerability. Lonza's acquisition of Synaffix in June 2023 further strengthens this offering, creating an integrated, end-to-end service that accelerates the path from DNA to Investigational New Drug (IND) application. Synaffix's GlycoConnect™ technology provides site-specific payload attachment, utilizing antibody glycan structures to increase stability. This approach, alongside HydraSpace®, which includes a polar spacer to enhance therapeutic index, and toxSYN®, which features a suite of potent cytotoxic agents, positions Synaffix as a leading player in ADC development. These technologies collectively aim to maximize therapeutic index—a crucial parameter in ADC efficacy, denoting the balance between therapeutic effect and side effect profile.\ The Role of Machine Learning in ADC Development BigHat Biosciences brings a powerful AI/ML-driven platform, Milliner™ , to this collaboration, with the potential to redefine ADC design and production speed. Traditional antibody engineering processes can be time-consuming and resource-intensive, requiring extensive laboratory work to develop antibodies with optimal biophysical properties. Milliner™ accelerates this process by integrating synthetic biology with advanced ML models, allowing rapid iteration and optimization of antibody candidates. This platform streamlines antibody design, enabling the development of antibodies with complex functions tailored to withstand the demands of drug conjugation without compromising therapeutic efficacy. Through this collaboration, Synaffix’s GlycoConnect™ technology benefits from BigHat’s precisely engineered antibodies, optimized for stable payload attachment and high binding affinity to target antigens. This union of ML and ADC technology not only facilitates the rapid progression of BigHat’s ADCs but also enhances their therapeutic potential by creating more robust, stable, and effective antibody-drug conjugates. Toward a Fully Integrated ADC Development Pathway The collaboration enables BigHat to leverage Lonza's full suite of ADC services, from antibody production to clinical trial supply. This integration allows BigHat to develop ADC candidates efficiently, reducing the timelines traditionally required for IND-enabling studies. The pathway, facilitated by Lonza’s state-of-the-art facilities, includes bioconjugation, drug product filling, and clinical batch production, all under a single quality system. This seamless, vertically integrated approach underscores Lonza’s commitment to accelerating ADC pipelines and helping biotech partners bring transformative therapies to market more swiftly. The demand for ADCs in the oncology sector continues to rise, spurred by the pressing need for safer, targeted treatments. However, manufacturing and development bottlenecks remain, as the complexity of ADCs requires specialized knowledge and infrastructure at every step of production. The integration offered by Lonza through Synaffix’s platform is a significant advantage, providing companies like BigHat with a streamlined path from initial design to clinical readiness. With Lonza’s recent facility expansion to handle high-potency vial filling, the infrastructure is in place to meet increasing market demands while maintaining the highest quality standards. Potential Impact of the Collaboration on ADC Therapeutics This partnership between Synaffix and BigHat Biosciences has implications far beyond individual drug candidates, potentially influencing the future of ADCs across the oncology landscape. By combining Synaffix’s established technology with BigHat’s AI-driven antibody discovery, the collaboration can produce ADCs that deliver drugs more precisely to tumor cells, thus enhancing both safety and efficacy. This approach directly addresses the unmet medical needs in difficult-to-treat cancers, where traditional therapies often fail due to limited selectivity and high toxicity. With Milliner™ , BigHat can continuously refine and optimize antibodies, leveraging ML to minimize the attrition rate of ADC candidates during preclinical and clinical stages. As ADCs are notoriously challenging to develop, with only a limited number of approved ADCs on the market, such advances in antibody design can lead to higher success rates, faster development timelines, and more accessible treatments for patients. Conclusion The collaboration between Lonza’s Synaffix and BigHat Biosciences is a notable advancement in the ADC field, showcasing how the synergy of machine learning and cutting-edge bioconjugation technology can propel next-generation oncology therapies. Synaffix’s platform offers a streamlined solution for developing ADCs with high stability, selectivity, and safety, while BigHat’s ML-powered Milliner™ platform provides a faster, more effective pathway to antibody design and optimization. This partnership not only strengthens each company’s competitive edge but also highlights the transformative potential of integrating biotechnology with artificial intelligence in cancer treatment innovation. As ADC technology continues to evolve, collaborations such as this set the stage for a future where AI-enhanced biologics bring safer, more effective therapies to patients worldwide. Author BioFocus Newsroom Previous Next

Biotech Startup Unveils Next-Generation Therapies, Including a Promising Once-Weekly Oral GLP-1 Peptide, Backed by Leading Global Investors. < Back Verdiva Bio Launches with $411M Funding to Revolutionize Obesity and Cardiometabolic Care Biotech Startup Unveils Next-Generation Therapies, Including a Promising Once-Weekly Oral GLP-1 Peptide, Backed by Leading Global Investors. Verdiva Bio , a newly established clinical-stage biopharmaceutical company, has launched with an impressive $411 million in Series A financing. The funding round was co-led by Forbion and General Atlantic, with additional participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital. The company is dedicated to developing innovative therapies targeting obesity, cardiometabolic disorders, and related complications. Its pipeline includes both oral and injectable treatments with the potential to be first-in-class or best-in-class. Notably, Verdiva's lead asset is a once-weekly oral GLP-1 peptide, VRB-101, which has demonstrated compelling efficacy potential in a Phase 1 study, confirming the viability of once-weekly dosing. Khurem Farooq, formerly the CEO of Aiolos Bio and Gyroscope Therapeutics, will lead Verdiva Bio as Chief Executive Officer. He is joined by a team of experienced drug developers and biotech professionals, including Chief Scientific Officer Jane Hughes and Chief Medical Officer Dr. Mohamed Eid. "People living with obesity and its complications deserve better options at each stage of their treatment journey," said Farooq. "We created Verdiva Bio to accelerate the development of differentiated medicines that address these significant unmet medical needs." Verdiva Bio's proprietary oral delivery technology is designed to enable patient-friendly dosing, greater scalability, and broader patient access. The company's portfolio also includes multiple amylin molecules (oral and subcutaneous agonists) and other undisclosed programs aimed at enhancing efficacy, improving tolerability, and promoting healthier weight loss. With this substantial financial backing and a robust pipeline, Verdiva Bio is poised to make significant strides in the treatment of obesity and cardiometabolic disorders, offering new hope to millions affected by these conditions worldwide. Author BioFocus Newsroom Previous Next

< Back 18th – 19th May, 2026 Edinburgh, UK International Brain Health Conference 2026 Inaugural international conference bringing together global leaders in neuroscience, clinical research, public health, and policy, with a central focus on protecting brain health before dementia develops. The inaugural International Brain Health Conference 2026 (IBHC 2026), hosted by Scottish Brain Sciences , will bring together researchers, clinicians, life sciences and pharmaceutical partners, policymakers and innovators to examine how advances in early detection and personalised medicine can be translated into practice. The conference will be held at the Sheraton Grand Hotel. Professor Craig Ritchie, CEO and Founder of Scottish Brain Sciences and Professor of Brain Health and Neurodegenerative Medicine at the University of St Andrews, said the field has shifted decisively towards identifying risk and disease processes well before dementia becomes clinically apparent. He emphasised that while the science now allows earlier identification, the more difficult task lies in embedding this knowledge within healthcare systems, public policy and routine clinical care, a gap the conference is intended to address. International faculty and cross-sector programme IBHC 2026 will feature an international faculty including Professor Jeff Cummings (University of Nevada), Professor Vanessa Raymont (University of Oxford), Professor Allan Young (Imperial College London), and Dr Francesca Farina (University of Chicago). The programme will span: Early detection, including imaging and fluid biomarkers Women’s brain health, menopause and sex-specific risk Brain health services and health economics Nutrition, sleep and mental health Comorbidities and infectious disease Global and population-level prevention strategies Professor Jeffrey Cummings will open the meeting with a keynote on therapeutic development. He noted that treatments for Alzheimer’s disease are progressing at pace, creating new opportunities to intervene in the earliest phases of illness. At the same time, he stressed the importance of maintaining momentum in prevention research, arguing that innovation in both treatment and prevention will be central to improving long-term brain health outcomes. A growing imperative for early intervention With dementia prevalence rising worldwide and health systems under sustained pressure, attention is increasingly turning to modifiable risk factors and earlier-stage intervention. IBHC 2026 aims to provide a forum for rigorous scientific exchange and collaboration across sectors at a point when the translation of research into service delivery is becoming ever more urgent. Early Bird registration, offering a 50% discount, is available until 31 March 2026. Further details and programme updates are available from Scottish Brain Sciences . Previous Register now Next

Streamline your workflow to set the pace. Accelerating cell therapy development and manufacturing. In a landscape of rapid market growth with a high pace of innovation, you need to keep up to realize your therapy’s full potential. Speed is therefore one of the most pressing challenges for cell therapy development and manufacturing. Discover how to streamline your workflow across cell isolation, activation, and expansion to stay ahead and help accelerate your treatments to patients. Learn more on how you can achieve your cell therapy quality goals and drive your performance forward, download now. First name Last name Country Email Institution City Would you like to have a Thermo Fisher Scientific bioprocessing specialist contact you for a quote, demo, sample, or to provide technical support? Choose an option I acknowledge and agree to the use of my contact information to receive messages about offerings by BioFocus, its brands, affiliates and/or third-party partners, consistent with the BioFocus Privacy Policy Read article